The Tuberculosis Drug Accelerator at year 10: what have we learned?

Nature medicine, Volume: 27, Issue: 8
August 1, 2021
Bree B Aldridge BB, David Barros-Aguirre D, Clifton E Barry CE, Robert H Bates RH, Steven J Berthel SJ, Helena I Boshoff HI, Kelly Chibale K, Xin-Jie Chu XJ, Christopher B Cooper CB, Véronique Dartois V, Ken Duncan K, Nader Fotouhi N, Fabian Gusovsky F, Philip A Hipskind PA, Dale J Kempf DJ, Joël Lelièvre J, Anne J Lenaerts AJ, Case W McNamara CW, Valerie Mizrahi V, Carl Nathan C, David B Olsen DB, Tanya Parish T, H Michael Petrassi HM, Alexander Pym A, Kyu Y Rhee KY, Gregory T Robertson GT, Jeremy Michael Rock JM, Eric J Rubin EJ, Betsy Russell B, David G Russell DG, James C Sacchettini JC, Dirk Schnappinger D, Michael Schrimpf M, Anna M Upton AM, Peter Warner P, Paul Graham Wyatt PG, Ying Yuan Y

The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in TB drug discovery by breaking down barriers among competing labs and institutions, has reached the 10-year landmark. We review the consortium’s achievements, advantages and limitations and advocate for application of similar models to other diseases.

Courtesy of the U.S. National Library of Medicine